Dr. Heimberger on the Variability of Responses in Glioblastoma ByAmy B. Heimberger, MDJune 25th 2021Amy B. Heimberger, MD, discusses the variability of responses in glioblastoma.
Dr. Heimberger on FGL2 as a Regulator of Tumor-Mediated Immune SuppressionByAmy B. Heimberger, MDNovember 21st 2015Amy B. Heimberger, MD, discusses the potential of FGL2 as a multi-modality regulator of tumor-mediated immune suppression in patients with glioblastoma.